Gunderson Dettmer Represented Leerink Partners and Goldman Sachs & Co. in $287.5M Arcus Biosciences Common Stock Offering

Gunderson Dettmer represented clients Leerink Partners and Goldman Sachs & Co. LLC as representatives of the underwriters in the common stock offering of Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on creating best-in-class therapies.

Arcus offered 15,755,000 shares of its common stock at an offering price of $18.25 per share, for total gross proceeds of approximately $287.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the common stock was offered by the company.

The share amounts reflect the exercise in full of the underwriters’ option to purchase additional shares of common stock. The offering closed on November 3, 2025.

The Gunderson deal team included corporate partner Marcia Hatch, Public Companies/Public Offerings partner Jeffrey Vetter and associates Elena Vespoli, Max Noreng and Amanda Sharp and senior paralegal Scott Paraker.

Companies
Leerink Partners
Goldman Sachs
Arcus Biosciences